ReviewOncology letters2025
Pathogenic role and therapeutic targets of nuclear factor-κB signaling pathway in cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- p62/SQSTM1-TRAF6/RIP1 complexes activate NF-κB-mediated PD-L1 expression and promote T-cell apoptosis in MKN45 gastric cancer cells.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nuclear factor-κB (NF-κB) signaling pathway not only exerts a notable role in inflammation and immune modulation but is also considered a key driver in the initiation and progression of cancer. NF-κB is closely associated with tumor cell proliferation, differentiation, apoptosis, invasion and metastasis, indicating its notable role in cancer pathogenesis. Based on research into the NF-κB pathway, the present article studied the biochemical processes involved in the NF-κB pathway, analyzed potential drug targets and inhibitors and clarified therapeutic strategies for targeting NF-κB in cancer treatment. The NF-κB signaling pathway consists of both classical and non-classical pathways and plays a fundamental role in multiple cancer processes, including cancer cell proliferation, apoptosis, autophagy, inflammation, tumor microenvironment interactions, therapy resistance, ion channel modulation, tumor heterogeneity, and epithelial-mesenchymal transition (EMT)-mediated migration, invasion and metastasis. Current therapeutic development has yielded diverse pharmacological agents targeting this pathway, including phytochemical-derived NF-κB inhibitors and synthetic molecules for cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.